Yuichi Ozawa is an expert in Oncology at Hamamatsu Medical Center (Japan). Yuichi Ozawa has authored 92 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 321 (community average: 125). How the SLR is computed.

LeadR Profile

Profile validated by the expert
Yuichi Ozawa Hamamatsu Medical Center Japan
321 ScienceLeadR Reputation 321
Network Map

Oncology

Subspecialties: Pulmonology - Internal Medicine - Nutrition

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Wakayama Medical University - Junior Associate Professor

2018 - 2026

Hamamatsu Medical Center

2022 - 2026

Wakayama Medical University - Researcher

2022 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 92

Citations

Citations: 1 633 1st author: 22 Last author: 1 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Paraneoplastic neurologic syndrome in a 65-year-old woman with small cell lung cancer.
PMID 42297399 — cells, lung, neoplasms, paraneoplastic syndromes, nervous system, lung neoplasms, small cell lung carcinoma
CMAJ20260
Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model From the Japan Lung Cancer Society Integrated Phase II-III Database.
PMID 42173719 — radiotherapy, esophagitis, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, chemoradiotherapy
Clin Lung Cancer20260
Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).
PMID 42150483 — safety, docetaxel, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, therapeutics
Lung Cancer20260
Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
PMID 41957135 — cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, weight loss, therapeutics
Br J Cancer20260
Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.
PMID 41847154 — safety, carcinoma, non-small-cell lung, chemoradiotherapy, mutation
JTO Clin Res Rep20250

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 2
Phase 2 1

By status:

Active not recruiting 1
Completed 1
Unknown 1

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 2

Main Topics

LeadR Networks

Main global connection map